Loading...
Indian Pharmaceutical Exporter · #5 for Dapagliflozin · $3.3M export value · DGFT Verified
Cipla Limited is the #5 Indian exporter of Dapagliflozin with $3.3M in export value and 96 verified shipments. Cipla Limited holds a 6.6% market share in Dapagliflozin exports across 8 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| 2 |
| 0.6% |
| TANZANIA | $12.5K | 1 | 0.5% |
| MADAGASCAR | $10.0K | 4 | 0.4% |
| ITALY | $1.3K | 3 | 0.1% |
Cipla Limited exports Dapagliflozin to 8 countries. The largest destination is CHINA accounting for 77.2% of Cipla Limited's Dapagliflozin shipments, followed by TURKEY (11.8%) and GHANA (8.7%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SINO UNIVERSAL PHARMACEUTICAL CO | CHINA | $915.4K | 19 |
| SINO UNIVERSAL PHARMACEUTICALCO LTD | CHINA | $250.0K | 5 |
| SINO UNIVERSAL PHARMACEUTICAL CO. | CHINA | $232.0K | 6 |
| SINO UNIVERSAL PHARMACEUTICALCO.LTD | CHINA | $200.0K | 4 |
| WORLDWIDE HEALTHCARE LTD | GHANA | $188.5K | 13 |
| HIGEN COMPANY | TURKEY | $141.5K | 6 |
| ROZ LOGISTICS | TURKEY | $129.2K | 6 |
| SINO UNIVERSAL PHARMACEUTICAL CO., | CHINA | $100.0K | 2 |
| SINO UNIVERSALPHARMACEUTICAL CO.LTD | CHINA | $66.1K | 2 |
| IBL LTD (HEALTHACTIV) | MAURITIUS | $13.2K | 2 |
Cipla Limited supplies Dapagliflozin to 19 buyers globally. The largest buyer is SINO UNIVERSAL PHARMACEUTICAL CO (CHINA), followed by SINO UNIVERSAL PHARMACEUTICALCO LTD (CHINA) and SINO UNIVERSAL PHARMACEUTICAL CO. (CHINA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $34.4M worth of Dapagliflozin through 5,104 shipments from 254 suppliers to 113 countries, serving 502 buyers globally. Cipla Limited contributes $3.3M to this total, accounting for 6.6% of India's Dapagliflozin exports. Cipla Limited ships Dapagliflozin to 8 countries through 19 buyers.
Cipla Limited's average Dapagliflozin shipment value is $34.2K per consignment, based on 96 shipments totaling $3.3M. The largest destination is CHINA (77.2% of Cipla Limited's Dapagliflozin exports).
Cipla Limited ranks #5 among 254 Indian Dapagliflozin exporters with a 6.6% market share. The top 3 exporters are MICRO LABS LIMITED ($7.7M), AJANTA PHARMA LIMITED ($5.2M), ALEMBIC PHARMACEUTICALS LIMITED ($4.8M). Cipla Limited processed 96 shipments to 8 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10 MG)(30 TABLETS/BOTTLE) (20874 PACKS X1X30S= 626220 NOS) | $150.0K | 3 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10 MG) (20874 PACKx1x30'S=626220 NOS) | $100.0K | 2 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10MG)(30 TABLETS/BOTTLE) (20855 PACKS X 1X30'S=625650 NOS) | $100.0K | 2 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10MG)(30 TABLETS/BOTTLE) (20909 PACKS X 1X30'S=627270 NOS) | $100.0K | 2 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10MG)(30 TABLETS/BOTTLE) (21004 PACKS X 1X30'S=630120 NOS) | $100.0K | 2 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10MG)(30 TABLETS/BOTTLE) (21021 PACKS X 1X30'S=630630 NOS) | $100.0K | 2 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10MG)(30 TABLETS/BOTTLE) (1X30'Sx20874PACK=626220NUM) | $50.0K | 1 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10 MG)(30 TABLETS/BOTTLE) (20799 PACKS X1X30S=623970 NOS) | $50.0K | 1 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10 MG) (30 TABLETS/BOTTLE) (20931 PACKx1x30'S=627930 NOS) | $50.0K | 1 |
| DAPAQUIS (DAPAGLIFLOZIN TABLETS 10 MG) (30 TABLETS/BOTTLE) (20874 PACKx1x30'S=626220 NOS) | $50.0K | 1 |
Cipla Limited exports 74 distinct Dapagliflozin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DAPAQUIS (DAPAGLIFLOZIN TABLETS 10 MG)(30 TABLETS/BOTTLE) (2 with 3 shipments worth $150.0K.
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | ALEMBIC PHARMACEUTICALS LIMITED | $4.8M | 95 | 3 | $50.0K |
| 4 | INVENTIA HEALTHCARE LIMITED | $4.6M | 111 | 11 | $41.3K |
| 5 | CIPLA LIMITED ★ | $3.3M | 96 | 8 | $34.2K |
| 7 | WATSON PHARMA PRIVATE LIMITED | $1.8M | 63 | 6 | $29.3K |
| 6 | MACLEODS PHARMACEUTICALS LTD | $1.7M | 34 | 8 | $50.0K |
Cipla Limited ranks #5 among 254 Indian Dapagliflozin exporters. Average shipment value of $34.2K compared to the market average of $135.5K. The closest competitors by value are ALEMBIC PHARMACEUTICALS LIMITED and INVENTIA HEALTHCARE LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,003 | 19.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 791 | 15.5% |
| DELHI AIR CARGO ACC (INDEL4) | 761 | 14.9% |
| DELHI AIR | 612 | 12.0% |
| Bombay Air | 194 | 3.8% |
| BANGALORE ACC (INBLR4) | 189 | 3.7% |
| BANGALORE AIR | 160 | 3.1% |
| NHAVA SHEVA SEA (INNSA1) | 136 | 2.7% |
Visual overview of India's dapagliflozin supplier profile for Cipla Limited — top suppliers, destinations, pricing, and trade routes
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Dapagliflozin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Dapagliflozin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 113+ countries, 502+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Dapagliflozin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Dapagliflozin. For current shipment-level data, contact TransData Nexus.